

Accepted Manuscript

Chlorin derivatives sterically-prevented from self-aggregation with high antitumor activity for photodynamic therapy

Irwin A.P. Linares, Kleber T. de Oliveira, Janice Rodrigues Perussi



PII: S0143-7208(17)30665-4

DOI: [10.1016/j.dyepig.2017.06.011](https://doi.org/10.1016/j.dyepig.2017.06.011)

Reference: DYPI 6032

To appear in: *Dyes and Pigments*

Received Date: 30 March 2017

Revised Date: 25 May 2017

Accepted Date: 7 June 2017

Please cite this article as: Linares IAP, de Oliveira KT, Perussi JR, Chlorin derivatives sterically-prevented from self-aggregation with high antitumor activity for photodynamic therapy, *Dyes and Pigments* (2017), doi: 10.1016/j.dyepig.2017.06.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Chlorin derivatives sterically-prevented from self-aggregation with high**
2 **antitumor activity for photodynamic therapy**

3
4 Irwin A. P. Linares^a, Kleber T. de Oliveira^b and Janice Rodrigues Perussi^a

5
6 ^aInstituto de Química de São Carlos, Universidade de São Paulo, São Carlos-
7 SP, Brazil

8 ^b Departamento de Química, Universidade Federal de São Carlos, São Carlos-
9 SP, Brazil

10
11 Corresponding author address:

12 Instituto de Química de São Carlos, Universidade de São Paulo, Av.
13 Trabalhador São-Carlense, 400. São Carlos-SP, Brazil.

14 13560-970

15 *janice@usp.br

16
17 **Abstract**

18 In this study two new chlorin derivatives sterically prevented from
19 aggregation were synthesised by the Diels-Alder reaction originated from
20 protoporphyrin IX dimethyl ester and 1-(2-hydroxyethyl)maleimide. The
21 compounds were fully characterised by ¹H-NMR, ¹³C-NMR, UV-Vis and high-
22 resolution mass spectroscopy (HRMS) and their photochemical properties such
23 as singlet oxygen quantum yield (ϕ_0), fluorescence quantum yield (ϕ_f) and
24 photodegradation were also evaluated. Furthermore, the partition coefficient
25 (log P) revealed that these compounds present amphiphilic properties. Studies

26 of the photodynamic action in tumour cells (HEp-2 and HeLa) and non-tumour
27 cells (Vero) were also performed in order to confirm the photodynamic therapy
28 (PDT) activity that was indicated by the preliminary photophysical studies.
29 Those phototoxicity results were 55–77% higher than the results obtained with
30 the commercial photosensitiser verteporfin. Finally, cytotoxic assays were
31 performed with the new photosensitiser candidates and cell death was
32 determined using fluorescence microscopy, which provided information about
33 the mechanisms of cell death. In general, we have obtained improved and
34 accessible compounds for PDT studies, as highlighted by the research
35 presented here.

36

37 **Keywords:** Chlorins, aggregation, amphiphilic character, photobleaching,
38 phototoxicity, mechanism of cell death

39

40

41

42

43

44

45

46

47

48

49

50

51

52 **Highlights**

53

54 New chlorin derivatives, sterically prevented from aggregation, were
55 synthesised by the Diels-Alder reaction.

56

57 Chlorin derivatives exhibit no aggregation in an aqueous medium (phosphate-
58 buffered saline).

59

60 The cytotoxicity of the chlorin derivatives in the tumour cells is higher than
61 verteporfin.

62

63 The mechanism of cell death occurs via an apoptotic process in three cell lines
64 after irradiation.

65

66

67

68

69

70

71

72

73

74

75

76


77 **1. Introduction**

78

79 Photodynamic therapy (PDT) is a non-invasive therapeutic method that
80 induces cell death of tumour cells by apoptosis or necrosis. The therapy uses
81 dyes or pigments (photosensitiser) that are capable of absorbing visible light
82 energy and transferring part of the absorbed energy to adjacent molecules. The
83 transfer of energy is usually to the oxygen (O_2) molecules which are present in
84 the tissues. This process leads to a series of photochemical reactions that
85 produce singlet oxygen, which is extremely toxic, and other reactive oxygen
86 species and free radicals, thus resulting in a strong cytotoxic effect and tumour
87 cell death [1–5].

88 Different types of photosensitisers, for example, porphyrin [6–8], chlorin [9–
89 11] and phthalocyanine [12, 13] derivatives, have been used in PDT studies.
90 Hematoporphyrin derivative (HpD) and Photofrin[®] are considered to be part of
91 the first generation of photosensitizers used in the therapy against cancer.
92 However, the strong aggregation of these photosensitizers in physiologic
93 medium, the low singlet oxygen quantum yields, and the short penetration of
94 red light (typically 630 nm) has resulted in limited use of these light-absorbing
95 molecules. Those limitations have led to the development of a new generation
96 of compounds with improved physical, chemical and photobiological properties
97 [14]. The most recent generation of compounds was developed to exhibit
98 characteristics such as intense absorption bands at longer wavelengths and
99 shorter skin photosensitivity periods, which would enable the treatments to
100 reach deeper tissues compared to the first generation of photosensitisers [15].

101 Chlorin derivatives, when compared with porphyrins, have a reduced double
102 bond in one β -position of one tetrapyrrolic ring [16, 17], resulting in a red-shifted
103 absorption band (640 to 680 nm) and allowing deeper light penetration in the
104 tissue [18–20]. Several chlorins have been approved for clinical use: Foscan[®],
105 talaporfin (NPe6) and verteporfin (Visudyne[®]) [21, 22]. Visudyne[®] is derived
106 from the natural protoporphyrin IX (PpIX) (Figure 1) [23–25]. It is used in the
107 treatment of age-related macular degeneration, choroidal neovascularization
108 due to secondary pathological myopia, and suspected ocular histoplasmosis
109 [26, 27]. In the last 15 years, this photosensitizer has been used as an efficient
110 compound in PDT studies and in clinical treatments for macular degeneration
111 [28].



113 **Fig. 1.** Protoporphyrin IX analogues.

114
115 Several approved photosensitisers, for example, Photofrin[®] [29, 30], Foscan
116 [31, 32], Laserphyrin [33, 34] and SnET2 [35, 36], are limited in their ability to be
117 applied to PDT because of skin photosensitivity caused by the slow clearance
118 of photosensitisers from the organism, low solubility, penetration of light and low
119 tumour-targeting efficacy [37]. Therefore, there are great challenges for

120 synthetic organic chemistry researchers to improve photosensitisers for PDT
121 treatments.

122 Different approaches have been used for the synthesis of chlorins derived
123 from PpIX dimethyl ester, which has resulted in better solubility and non-
124 aggregation in physiological medium [38–41]. Recently, chlorin derivatives
125 synthesised by the Diels-Alder reaction between diene-appended porphyrins
126 and maleimides yielded L-shape chlorin derivatives. These L-shape structures
127 prevent the aggregation caused by the strong attraction between the π -systems
128 of the polyaromatic heterocycles, thus resulting in molecules with high singlet
129 oxygen quantum yields [39, 41]. Therefore, in this study, we carried out the
130 synthesis of a new chlorin derivatives by the Diels-Alder reaction between the
131 PpIX dimethyl ester and different maleimides. We characterised the new
132 photosensitiser derivatives and investigated their photodynamic activity,
133 cytotoxicity, phototoxicity, photobleaching, cell death and accumulation in cells.

134

135 **2. Materials and Methods**

136

137 **2.1 Reagents and measurements**

138

139 All reagents were of analytical grade and were purchased from Aldrich or
140 national suppliers. Solvents and reagents that were used for the synthesis were
141 only used after purification according to standard procedures [42]. Ultrasound
142 irradiation was used to deoxygenate the toluene for the Diels-Alder reactions.
143 ^1H and ^{13}C -NMR spectra were recorded on a Bruker Avance 400 spectrometer
144 at 400.13 MHz and 100.13 MHz, respectively, using CDCl_3 as the solvent and

145 tetramethylsilane (TMS) as the internal reference. The chemical shifts were
146 expressed in parts per million (ppm) and the coupling constants (J) in hertz
147 (Hz). High-resolution mass spectrometry (HRMS) analyses were obtained using
148 the ESI-LTQ orbitrap (Thermo Scientific) and Xcalibur 2.1 analysis processing
149 software. The UV-Vis absorption spectra analyses of the chlorin derivatives
150 were performed using a Perkin Elmer Lambda 25 spectrophotometer.

151 Preparative purifications were carried out by using column chromatography
152 and silica gel 200 and 400 mesh, and preparative thin-layer chromatography
153 (TLC) and analytical TLC were conducted on TLC Silica gel 60 aluminium
154 sheets (1mm thick) (Merck). The light-source for photobleaching was a 660 nm
155 diode laser (FTC 500, OPTO, Sao Carlos-SP, Brazil) in the PDT/iPDT mode.

156 The partition coefficients and fluorescence measurements of the chlorin
157 derivatives were performed using a spectrophotometer (HITACHI U-2800,
158 Japan) and a spectrofluorometer (HITACHI F-4500, Japan), respectively, with
159 10 mm path length quartz cuvettes. The light-source used for the photodynamic
160 treatment was an irradiation table called Biotable that contained a series of 660
161 ± 10 nm LEDs with a fluence rate of 27.6 mWcm^{-2} (LAT, IFSC-USP). The
162 absorbance measurements of the formazan dye after the phototoxic assays
163 were read in a Biotek-Synergy HT spectrophotometer. To visualise cell death, a
164 fluorescence microscope (Olympus BX41) was used with the following
165 parameters: 20X magnification, excitation filter of 460/90 nm, dichromatic mirror
166 of 50 nm and barrier filter of 520 nm. Images were captured with an Olympus
167 DP72 digital camera.

168

169

170 2.2 Synthesis of 4,10-Dioxatricyclo[5.2.1.0]dec-8-ene-3,5-dione (**3**)

171

172 The synthesis of 4,10-Dioxatricyclo[5.2.1.0]dec-8-ene-3,5-dione (**3**) was
173 carried out following methods reported in a previous publication [43]. In a 100
174 mL round-bottom flask, maleic anhydride (**1**) (10.00 g, 102 mmol), toluene (50
175 mL), and furan (**2**) (7.5 mL, 103.1 mmol) were stirred at room temperature
176 under an inert atmosphere for 24 h. The product was obtained after filtration
177 and washing of the precipitate with cold diethyl ether (80% yield, 13.57 g, 81.73
178 mmol). ¹H-NMR (400 MHz, DMSO-d₆) δ 6.56 (s, 2H), 5.32 (s, 2H), 3.29 (s, 2H);
179 ¹³C-NMR (100 MHz, DMSO-d₆) δ 172.0, 137.3, 82.1, 49.5.

180

181 2.3 Synthesis of 4-(2-Hydroxy-ethyl)-10-oxa-4-aza-tricyclo [5.2.1.0]-dec-8-ene-
182 3,5-dione (**4**)

183

184 The synthesis of 4-(2-Hydroxy-ethyl)-10-oxa-4-aza-tricyclo [5.2.1.0]-dec-8-
185 ene-3,5-dione (**4**) was carried out following methods reported in a previous
186 publication [44]. A 50 mL two-neck round-bottom flask was adapted with a reflux
187 condenser, the intermediate **3** (5.0 g, 30.1 mmol) was combined with dry
188 methanol (15 mL). After stabilizing the magnetic stirring and the reaction
189 temperature at 0°C, ethanolamine was added dropwise (1.84 g, 30.12mmol).
190 The mixture was refluxed for 24 h. The methanol was then distilled off under
191 reduced pressure, and the product was recrystallised from diethyl ether at -
192 20°C. The crystals were collected by filtration and washed with cold diethyl
193 ether in 61% yield. (3.81 g, 18.21 mmol). ¹H-NMR (400 MHz, DMSO-d₆) δ 6.53

194 (s, 2H), 5.10 (s, 2H), 3.39 (s, 4H), 2.90 (s, 2H); ¹³C-NMR (100 MHz, DMSO-d₆)
195 δ 176.9, 136.9, 80.7, 57.7, 47.6, 41.0.

196

197 2.4 Synthesis of 1-(2-Hydroxyethyl)-1H-pyrrole-2,5-dione (**5**)

198

199 The synthesis of 1-(2-Hydroxyethyl)-1H-pyrrole-2,5-dione (**5**) was carried out
200 following methods reported in a previous publication [43]. In a 50 mL round-
201 bottom flask adapted with a flux condenser and magnetic stirring, the
202 intermediate **4** (2.30 g, 10.99 mmol) was combined with toluene (30 mL). The
203 reaction was refluxed for 7 h. The resulting mixture was immediately filtered,
204 and the product crystallised from toluene in 81% yield (1.25 g, 8.87 mmol). ¹H-
205 NMR (400 MHz, DMSO-d₆) δ 7.01 (s, 2H), 4.78 (br, 1H), 3.46 (br, 4H); ¹³C-NMR
206 (100 MHz, DMSO-d₆) δ 171.1, 134.5, 57.9, 39.9.

207

208 2.5 Synthesis of protoporphyrin IX dimethyl ester (**7**)

209

210 The synthesis of protoporphyrin IX dimethyl ester (**7**) was carried out
211 following methods reported in a previous publication [39] in 75% (1.59 g, 2.70
212 mmol). ¹H-NMR (CDCl₃, 400 MHz) δ ppm: -3.69 (s, 2H), 3.28 (t, 4H, J = 7.7 Hz);
213 3.56 (s, 3H); 3.61 (s, 3H); 3.62 (s, 6H), 3.65 (s, 3H); 3.70 (s, 3H); 4.34 (t, 4H, J
214 = 7.7 Hz); 6.16 (d, 2H, J = 11.5 Hz); 6.35 (d, 2H, J = 17.8 Hz), 8.27 (dd, 2H, J
215 = 17.9 Hz, J = 11.3 Hz); 9.92 (s, 3H); 9.93 (s, 1H); 10.05 (s, 3H); 10.06 (s, 3H).

216

217

218 2.6 Diels-Alder reaction between protoporphyrin IX dimethyl ester (**7**) and 1-(2-
219 Hydroxyethyl)-1H-pyrrole-2,5-dione (**5**)

220

221 The syntheses were carried out following the modification of a procedure
222 that has been previously published [39]. In a glass pressure tube, were added **7**
223 (60 mg, 0.1 mmol), dry toluene (5 mL) and **5** (282 mg, 2 mmol). The reaction
224 was stirred at 125°C for 24 h. The reaction was monitored by TLC and UV-Vis
225 spectroscopy in order to verify the consumption of the starting material. The
226 reaction products were purified by flash column in silica gel, and preparative
227 TLC chromatography using chloroform, ethyl acetate and methanol in a 5:4:1
228 ratio as eluent. Two chlorin derivatives, **8-a** and **8-b**, were crystallised from
229 CH₂Cl₂ and hexane in 33 and 34%, respectively.

230

231 2¹,2²[N,N-dicarbonil-N-4-(2-hydroxyethyl)phenyl]-13,17-bis[2-
232 (methoxycarbonyl)ethyl]-2,7,12,18-tetramethyl-8-vinyl-2,2¹,2²,2³-
233 tetrahydrobenzo[b]porphyrin (**8a**): ¹H-NMR (CDCl₃, 400 MHz) δ (ppm): -2.49 (s,
234 2H,); 2.01 (s, 3H); 3.13 - 3.17 and 3.20 - 3.24 (m, 9H); 3.40 (s, 3H); 3.42 - 3.45
235 (m, 2H); 3.50 (s, 3H); 3.54 (s, 3H); 3.66 and 3.69 (s, 6H); 3.75 - 3.79 (m, 1H);
236 4.18 (t, 2H, J=7.8 Hz); 4.31 (t, 2H, J=7.7 Hz), 4.51 (d, 1H, J=8.4 Hz); 6.15 (dd,
237 1H, J=1.4 Hz, J=11.5 Hz); 6.34 (dd, H, J=1.4 Hz and J=17.8 Hz); 7.35 (t, 1H,
238 J=5.3 Hz); 8.17 (dd, 1H, J=17.8 Hz and 11.5 Hz); 9.07 (s, 1H); 9.30 (s, 1H);
239 9.70 (s, 1H), 9.86 (s, 1H); ¹³C-NMR (CDCl₃, 100 MHz) δ (ppm): 11.4, 11.6; 12.3,
240 21.5,21.9, 25.6, 26.5,36.6, 37.0, 38.5, 50.1, 51.7, 51.8, 52.3, 90.4, 93.4, 97.9,
241 99.8, 115.6, 121.4, 129.2, 129.8, 130.9, 132.6, 133.7, 133.9, 136.2, 136.5,
242 138.3, 139.6, 149.5, 151.0, 151.3, 152.2, 165.9, 173.4, 173.8,174.8,178.5;

243 **HRMS (ESI-LTQ orbitrap velos):** m/z calculated for $[M+H]^+$ 732.33716, found
244 732.33918.

245

246 $2^1,2^2$ [N,N-dicarbonil-N-4-(2-hydroxyethyl)phenyl]-8,12-bis[2-
247 (methoxycarbonyl)ethyl]-2,7,12,18-tetramethyl-8-vinyl-2,2¹,2²,2³-
248 tetrahydrobenzo[b]porphyrin (**8b**): ¹H-NMR (CDCl₃, 400 MHz) δ (ppm): -2.45 (s,
249 2H.); 2.01 (s, 3H); 3.13 - 3.18 and 3.20 - 3.25 (m, 9H); 3.41 (s, 3H); 3.41 (s,
250 3H); 3.45 (s, 3H); 3.50 - 3.57 (m, 2H); 3.62 (s, 3H); 3.64 and 3.65 (s, 6H); 3.74 e
251 3.79 (m, 1H); 4.17 (t, 2H, J=7.8 Hz); 4.30 (t, 2H, J=7.7 Hz), 4.50 (d, 1H, J=8.4
252 Hz); 6.12 (dd, 1H, J=1.4 Hz, J=11.5 Hz); 6.34 (dd, H, J=1.4 Hz, J=17.8 Hz);
253 7.34 (t, 1H, J=5.4 Hz); 8.13 (dd, 1H, J=6.3 Hz and 17.8 Hz); 9.23 (s, 1H); 9.24
254 (s, 2H), 9.69 (s, 1H), 9.76 (s, 1H); ¹³C-NMR (CDCl₃, 100 MHz) δ (ppm): 11.2,
255 11.7, 12.4, 21.6, 21.9, 25.6, 26.6, 36.7, 37.1, 38.6, 50.1, 51.7, 51.8, 52.2, 89.9,
256 94.1, 98.4, 99.4, 116.0, 120.9, 129.9, 130.4, 131.2, 133.3, 133.8, 135.9, 136.8,
257 137.3, 138.0, 139.7, 149.6, 150.6, 151.4, 152.8, 165.6, 173.4, 173.8, 174.7,
258 178.5; **HRMS (ESI-LTQ orbitrap velos):** m/z calculated for $[M+H]^+$ 732.33698,
259 found 732.33918.

260

261 2.7 Singlet oxygen quantum-yield measurement

262

263 The singlet oxygen quantum yields (Φ_{Δ}) of **8-a** and **8-b** were determined
264 from the intensity of the phosphorescence decay at 1270 nm [45]. The data
265 were recorded with a time-resolved NIR fluorometer (Edinburgh Analytical
266 Instruments) at the Departamento de Bioquímica, Instituto de Química,
267 Universidade de São Paulo. The NIR fluorimeter was equipped with an Nd:YAG

268 LASER (Quatel) and a system optical parameter oscillator (OPO) allowing to
269 choose the desired wavelength in which the samples were excited at 420 nm (5
270 ns pulse). The emitted light was passed through silicon, an interference filter
271 and a monochromator before detection with an NIR photomultiplier
272 (Hamamatsu Co. R5509). The singlet oxygen lifetime was determined by
273 applying first-order exponential fittings to the phosphorescence decay curve.
274 The Φ_{Δ} values were obtained using verteporfin as a reference ($\Phi_{\Delta}=0.77$) [46].
275 This procedure was performed in triplicate.

276

277 2.8 Fluorescence quantum yield measurements

278

279 The fluorescence quantum yields were determined using Rhodamine B in
280 ethanol as a reference ($\Phi_f = 0.65$) [47]. The solutions of the chlorin derivatives,
281 **8a** and **8-b**, were prepared in DMSO from stock solutions. The absorbance was
282 maintained at approximately 0.04 and 0.05 to avoid the inner filter effect.
283 Excitation of both chlorins was performed at 510 nm, and the emission spectra
284 were recorded. This procedure was performed in triplicate.

285

286 2.9 Photobleaching studies

287

288 A solution of **8-a** or **8-b** was prepared in CH_2Cl_2 with an absorbance value
289 of approximately 1. The solution was irradiated at 661 nm for 10 minutes, with 1
290 min intervals, using a laser potency of 50 mW. The absorbance spectra were
291 monitored after each irradiation interval in order to observe whether
292 photobleaching of the chlorin derivatives occurred [17].

293 2.10 Determination of the partition coefficients in a solution of 1-octanol and
294 PBS

295

296 The partition coefficients were determined at room temperature by a spread
297 shake-flask method [48]. The phosphate-buffered saline (PBS) and 1-octanol
298 were mixed for five days to promote solvent saturation in both phases.
299 Compounds **8-a** or **8-b** were dissolved in the organic phase. Subsequently,
300 equal amounts of PBS, 1-octanol and photosensitisers at $1.0 \times 10^5 \text{ mol L}^{-1}$ were
301 mixed for 3 h under magnetic stirring and protection from light. The phase
302 separation was followed by 10 min of centrifugation at 1000 rpm. The UV-Vis
303 absorption spectra were measured before and after partitioning, and the
304 differences were measured at the Soret band.

305

306 2.11 Aggregation study

307

308 Tetrapyrrolic molecules, such as chlorin derivatives, frequently aggregate in
309 an aqueous medium due to the strong attractive interactions between the π -
310 systems of the polyaromatic compound and the low interaction with the solvent.
311 To evaluate the aggregation process, compounds **8-a** or **8-b** and verteporfin,
312 were evaluated in different concentrations. Each sample solution was prepared
313 in DMSO and PBS in order to determine the presence or absence of
314 aggregation in solution. UV-Vis analyses were monitored for changes in the λ_{max}
315 band of the spectra.

316

317

318 2.12 Phototoxicity assay

319

320 In this study, two cell lines were used: HeLa cell line (CCL-2TM, ATCC,
321 USA), a human cervical carcinoma cell, and HEP-2 (CCL-23TM), an epithelial
322 tumour-cell line. These cell lines were grown in Iscove's Modified Dulbecco's
323 media (Sigma-Aldrich) and were supplemented with 10% foetal bovine serum
324 (FBS, Cultilab) and 0.01% antibiotics (penicillin and streptomycin, Cultilab) in 75
325 cm² cell culture flasks incubated at 37°C and 5% CO₂. The cells were seeded
326 (5x10⁴ cells mL⁻¹) in 96-well plates and underwent photodynamic treatments.
327 Cell viability was evaluated using the MTT (3,4,5-dimethylthiazol-2,5-diphenyl
328 tetrazolium bromide) assay [49]. This method is based on the ability of viable
329 cells with active metabolisms to use mitochondrial dehydrogenase enzymes to
330 cleave the tetrazolium rings of the yellow MTT and form an insoluble precipitate
331 (formazan crystals) inside of the cells [50]. Cells were incubated for 2 h in the
332 absence of light with the photosensitisers and different concentrations of **8-a**
333 and **8-b**. Subsequently, the cells were irradiated at 660 ± 10 nm using the
334 Biotable at two time intervals in order to obtain two different light doses: 3.0 and
335 6.0 J cm⁻².

336 At 48 h post-irradiation, the medium was removed and the cells were
337 incubated for 3 h with an MTT solution in culture medium added to each well of
338 the plate. Following the incubation period, the solution that contained MTT was
339 removed and the cells washed with 100 µL PBS. The formazan crystals were
340 solubilised in 100 µL of absolute ethanol and 100 µL of isopropyl alcohol. The
341 absorbance was read at 570 nm. The cell survival rate (%) was assessed in
342 relation to the photosensitiser concentration. The average inhibitory

343 concentrations (IC_{50}) of the photosensitisers were determined. We also carried
344 out an analysis of controls with no treatment, cells treated only with
345 photosensitisers (not irradiated), and cells treated only with irradiation (without
346 photosensitiser).

347

348 2.13 Cell death detection by acridine orange/ethidium bromide (AO/EB)
349 staining

350

351 HeLa and Hep-2 cells were seeded (5×10^4 cells mL^{-1}) in sterile chamber
352 slides with culture medium. After 24 h the cells were incubated with different
353 concentration of **8-a** or **8-b** for 2 h. After the incubation period, the cells were
354 washed with PBS, maintained in culture medium, and then irradiated with a light
355 dose of 3 or 6 $J\ cm^{-2}$. After 48 h, the cells were stained with a mixture of
356 ethidium bromide and acridine orange ($100\ \mu g\ mL^{-1}$). The labelled cells were
357 visualised by fluorescence microscopy [51].

358

359 2.14 Statistical Analysis

360

361 The data from the biological assays were analysed by one-way analysis of
362 variance (ANOVA) followed by Student-Newman-Keuls multiple-comparisons
363 test (Graph Pad InStat software). Differences were considered significant when
364 $p \leq 0.05$.

365

366

367


368 **3. Results and discussion**

369

370 **3.1 Chlorin derivatives syntheses**

371

372 The preparation of protoporphyrin IX dimethyl ester (PpIX) (**7**), described in
 373 scheme 1, began with a process of elimination of two hydroxyl (-OH) groups of
 374 hematoporphyrin (Hp) (**6**). Then, an esterification in the presence of methanol
 375 and sulfuric acid (H₂SO₄) (5%) was performed maintaining the protection from
 376 light. The final product **7** was obtained after solvent evaporation and a simple
 377 crystallization from CHCl₃:MeOH (1:3). Compound **7** was isolated in 79% yield
 378 and characterised by ¹H-NMR and UV-Vis in order to confirm its identity and
 379 purity.



380


381

382 **Scheme 1.** Synthesis of protoporphyrin IX dimethyl ester from hematoporphyrin.

383

384 After obtaining **7**, the synthesis of the dienophile maleimide **5** was
 385 performed, as described in scheme 2. For this purpose, the Diels-Alder adduct,
 386 **3**, was obtained from maleic anhydride (**1**) and furan (**2**) (80% yield) [43]. Next,
 387 ethanolamine was added to compound **3**, yielding the maleimide **4** (61%) [44].
 388 Compound **5** was obtained after a retro-Diels-Alder reaction in 81% yield [43].
 389 The Diels-Alder reaction between **5** and **7** was performed in glass-pressure

390 tubes (toluene at 125°C, 24h), and catalytic amounts of BHT were used to avoid
 391 polymerised by-products (Scheme 3).




392

393 **Scheme 2.** Synthesis of N-(hydroxyethyl)maleimide.

394

395 The chlorin derivatives **8-a** and **8-b** were separated by preparative TLC over
 396 silica at a 1:1 ratio, resulting in 68% overall yield. These compounds were fully
 397 characterised by ¹H-NMR, ¹³C-NMR, HRMS and UV-Vis.



398

399 **Scheme 3.** Synthesis of chlorins **8-a** and **8-b**.

400

401

402 3.2 Singlet Oxygen Quantum Yields (Φ_{Δ}) measurements

403

404 The singlet oxygen quantum yields of **8-a**, **8-b** and verteporfin (standard)
 405 were determined from equation (1). This term is used to describe the
 406 measurement of the efficiency in which molecules are able to absorb light and
 407 convert molecular oxygen ($^3\text{O}_2$) to singlet oxygen ($^1\text{O}_2$) [52].

408

$$409 \quad \Phi_{\Delta} = \frac{Abs_{Std} I_{PS} \tau_{Std}}{Abs_{PS} I_{Std} \tau_{PS}} \Phi_{\Delta}^{Std} \quad (1)$$

410

411 Where (Φ_{Δ}) represents the singlet oxygen quantum yield of the sample and
 412 (Φ_{Δ}^{Std}) is the standard (Verteporfin) singlet oxygen quantum yield. Abs^{PS} and
 413 Abs^{Std} are the absorbance values of the photosensitiser samples and the
 414 standard. I_{abs} and I_{abs}^{Std} are the maxima intensity of phosphorescence decay
 415 curve for the sample and the standard. τ_{PS} and τ_{Std} are the single-oxygen
 416 lifetime of the sample and the standard, respectively. The solutions of **8-a**, **8-b**
 417 and verteporfin were solubilised in DMSO. The chlorins **8-a** and **8-b** showed
 418 similar singlet oxygen quantum yields when compared to verteporfin (Table 1).

419

420 **Table 1.** Quantum yield values of singlet oxygen formation (Φ_{Δ}) and
 421 fluorescence (Φ_f) of verteporfin and of chlorins **8-a** and **8-b**. Data are expressed
 422 as average \pm SD.

	(Φ_{Δ})	(Φ_f)
Verteporfin	0.77 \pm 0.02 ^[46]	0.0085 \pm 0.0006 ^{α}
8-a	0.75 \pm 0.02	0.0096 \pm 0.0003
8-b	0.73 \pm 0.03	0.0110 \pm 0.0006 ^{*, α}

423

Experiment was performed in triplicate at 20°C

424

 ^{α} Statistically significant difference from CHL-OH-A ($p < 0.05$)

425

* Statistically significant difference from Verteporfin ($p < 0.01$)

426 3.3 Fluorescence Quantum yields (Φ_f) measurements

427

428 The fluorescence quantum yield is defined as the number of emitted
429 photons relative to the number of absorbed photons and was determined using
430 equation (2) [53].

431

$$432 \quad \Phi_f = \Phi_f^{Std} \frac{F \cdot A_{Std} \cdot n^2}{F_{Std} \cdot A \cdot n_{Std}^2} \quad (2)$$

433

434 Where (Φ_f^{Std}) represent the fluorescence quantum yield of the standard. F and
435 F_{Std} represent the areas under the fluorescence emission curves for the sample
436 and standard, respectively. A and A_{Std} are the absorbance of the chlorin
437 derivatives and the standard acquired from the same amount of solution used to
438 measure the fluorescence emission spectra of both. The parameter, n and n_{Std}
439 are the refractive indices for the used solvents. Solutions of each compound, **8-**
440 **a**, **8-b**, were prepared in DMSO and exhibited emissions at 676 nm with
441 quantum yield of fluorescence values comparable to the verteporfin (standard)
442 (table 1).


443

444 3.4 Photobleaching studies

445

446 Photostability is a physicochemical property important to photosensitisers in
447 general, since during the irradiation time, the molecule may lose its
448 photodynamic activity due to chemical changes in its structure resulting in small
449 fragments (photo-products) that have no appreciable absorption in the visible
450 region [54]. The synthesised compounds **8-a** and **8-b** showed a slight

451 photobleaching effect, depending on the irradiation time. A reduction of
452 approximately 5% in the absorbance band at both 404 nm (Soret band) and 668
453 nm (Q-band) was observed, thus allowing to consider these new chlorin
454 derivatives as photo-stable under visible light irradiation (Figure 2).



455

456 **Fig. 2.** Photobleaching study of the chlorin **8-a** (inset: expansion of Soret band).

457

458 3.5 Partition coefficient in 1-octanol/PBS (Log P)

459

460 The lipophilicity of the synthesised chlorin derivatives and verteporfin was
461 determined from the partition coefficient. The log P is defined as the ratio of
462 concentrations of the photosensitiser at equilibrium between the organic and
463 aqueous phases [55, 56]. This feature is important since it allows the
464 incorporation of molecules within the cell. Compounds **8-a**, **8-b** and verteporfin
465 were solubilised in 1-octanol relative to the aqueous phase (PBS). The log P for
466 each compound was calculated according to an adaptation of the method first
467 proposed by Pooler and Valenzano [57], because the studied photosensitisers
468 are sparingly soluble in the aqueous phase (Equation 3).

469

$$\log P = \log \frac{(A_{\lambda d})}{(A_{\lambda o} - A_{\lambda d})} \quad (3)$$

471

472 Where $A_{\lambda o}$ is the absorption solution before the partition and $A_{\lambda d}$ is the
 473 absorption solution after the partition at wavelength 404 nm. Positive log P
 474 values mean that the compound exhibit lipophilic characteristics ($\log P > 0$) and
 475 negative log P values mean that it shows a hydrophilic character ($\log P < 0$)
 476 (Table 2). The photosensitiser candidates **8-a** and **8-b** were less lipophilic than
 477 verteporfin when the absorption spectrum before and after partition was
 478 considered. This means that a number of molecules of chlorin (**8-a** or **8-b**) were
 479 transferred toward the aqueous phase, resulting in stronger amphiphilic
 480 characteristics and displaying a stronger interaction with the polar environment
 481 [58, 59]. This affinity allows the compounds to diffuse through the aqueous
 482 medium and easily across the cell membrane.

483

484 **Table 2:** Partition coefficients using a mixture of 1-octanol and phosphate-buffer
 485 saline (PBS). Data are expressed as average \pm SD.

Photosensitiser	Partition Coefficient (Log P)
Verteporfin	1.61 \pm 0.10
8-a	1.20 \pm 0.04*
8-b	1.17 \pm 0.03*

486 * Statistically significant difference from Verteporfin ($p < 0.001$)

487

488 The chlorins showed amphiphilic characteristics and log-P values that were
 489 approximately 25% lower than verteporfin (which presented lipophilic
 490 characteristics). This result shows the importance of hydrophilic groups
 491 attached to the chlorin structure, which increases the solubility in an aqueous
 492 medium without changing the penetration power through the plasmatic

493 membrane of cells. Once verteporfin has no hydrophilic groups in its structure, it
494 becomes more lipophilic and less soluble in aqueous medium. This result is
495 also consistent with the determined Φ_{Δ} values.

496

497 3.6 Aggregation study

498

499 The concentrations of **8-a**, **8-b** and verteporfin analysed by UV-Vis
500 spectroscopy were on the same scale of those used in the cytotoxic assays.
501 Chlorin derivatives **8-a** and **8-b** exhibited no aggregation in an aqueous medium
502 (PBS) of up to $10 \mu\text{mol L}^{-1}$ because the “L shape” of the molecules prevented
503 some π -stacking interactions (Figure 4A and 4B). Verteporfin showed a shift of
504 20 nm in the Soret band, which was caused when the strong interactions of the
505 π -orbitals of the aromatic ring induced aggregation (Figure 3) [40]. Once again,
506 the synthesised photosensitiser candidates appeared to be more adequate
507 options for PDT.

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533 **Fig. 3.** Aggregation study of (A) Chlorin **8-a** (B) Chlorin **8-b** and (C) Verteporfin in PBS
 534 by UV-Vis spectroscopy.


535

536 3.7 Phototoxicity assay


537

538 The phototoxic assays of **8a**, **8-b** and verteporfin were performed at two
 539 light doses (3 and 6 J cm^{-2}) with a light intensity of 27.6 mW cm^{-2} in the tumour
 540 cell lines HEP-2 and HeLa and in the non-tumour cells Vero. These assays
 541 were important for the determination of the medium inhibitory concentrations
 542 (IC_{50}) of each molecule using the MTT colorimetric method.


543



544



552



560

561 **Fig. 4.** Medium inhibitory concentrations (IC₅₀) of the chlorins **8-a**, **8-b** and verteporfin
 562 in HeLa, HEP-2 and Vero cells. The cells were incubated for 2 h, following by red
 563 irradiation (660 nm) and light doses at (A) 3 and (B) 6 J cm⁻². The MTT assay was
 564 performed to determine the cell viability after 48 h of irradiation. The results are
 565 expressed as means ± standard deviation (SD). *, α : statistically significant difference
 566 from Vero cells ($p < 0.001$; $p < 0.05$). Δ , β : statistically significant difference from HeLa
 567 cells ($p < 0.01$; $p < 0.001$).

568

569 Compounds **8-a**, **8-b** and verteporfin showed a lower cytotoxicity in normal cell
570 lines (Vero) for the two tested light doses (Fig. 4), indicating a good selectivity
571 for the tumour cell. This can be due to various factors such as an increase in
572 the permeability of tumour cells, which has been observed in many experiments
573 using animal models [60]. In addition, the location of photosensitisers within the
574 tumour cell may be different compared to normal cells because of the selective
575 retention of each cell such as those with low pH [61], over-expression of low-
576 density lipoprotein receptors [62] (LDL, apoB/E), and the over-expression of
577 some tumour associated macrophages [63]. The chlorin **8-a** showed the lowest
578 IC_{50} value, which means the highest cytotoxicity in HeLa tumour cells ($26.9 \pm$
579 1.9) at a dose 6 J cm^{-2} , and they were 57% more cytotoxic than verteporfin; the
580 chlorin **8-b** exhibited the lowest value of IC_{50} in the HEP-2 cells (9.2 ± 1.1), and
581 they were 77% more cytotoxic than verteporfin at the same light dose.
582 Furthermore, the tests were carried out in the dark for the three compounds (**8-**
583 **a**, **8-b** and verteporfin) which demonstrated a very low cytotoxicity in the studied
584 cells. These achievements highlight the important phototoxic effects of newly
585 synthesised photosensitiser candidates and the promising possibility of using
586 these chlorins in PDT.

587

588 3.8 Cell death detection by acridine orange/ethidium bromide (AO/EB) staining

589

590 In order to determine the mechanism of cell death, cells were labelled with a
591 mixture of acridine orange and ethidium bromide after 48h irradiation. Cell
592 differentiation was analysed with a 20X objective and treated with $1 \times 10^{-8} \text{ mol L}^{-1}$
593 of chlorin **8-a** or **8-b**. The three cell lines (HeLa, HEP-2 and Vero) that were

594 treated with the shorter irradiation time (3 J cm^{-2}) showed a low percentage of
595 cell death (30%). However, those with the largest irradiation time (6 J cm^{-2})
596 showed a late apoptotic process (condensation and fragmentation of chromatin
597 stained in orange) and a few cells in a necrotic state (red nuclei stained) caused
598 by the loss of the integrity of the cytoplasm membrane (Figure 5B [a-c]).

599 Explanations for this difference include the time length of light incidence in
600 order to obtain different light doses using the same light source on molecules
601 photosensitiser (in ground state), leading to different number of molecules in the
602 excited triplet state (PS^*) and to generation of reactive oxygen species and the
603 higher oxidative stress in tumour cells [64]. These species play an important
604 role in the intrinsic pathway of apoptosis signalling because mitochondrial DNA
605 damage is responsible for respiratory chain electron [65]. Morphological
606 information observed by differential staining with AO/EB suggests that **8-a** and
607 **8-b** induce cell death by apoptosis in all the studied cell lines. However, the
608 route of induction of apoptosis is not completely understood.

609

610

611

612

613

614

615

616

617

618

619

A

B

620

621

622

623

624

625

626

627

628

629

630

631

632


633

634

635

636

637



638

639 **Fig. 5.** Fluorescence microscopy images of three cell lines incubated with 1×10^{-8} mol L⁻¹

640 ¹ chlorin 8-b followed by red light irradiation (660 nm). (A) Untreated (control) cells: (a)

641 HeLa (b) HEP-2 and (c) Vero. (B) Apoptotic cells after 48h of treatment (6 J cm^{-2}): (a)

642 HeLa (b) HEP-2 and (c) Vero, respectively.

643

644

645

646 **4. Conclusion**

647

648 In this study, we synthesised two chlorin derivatives, **8-a** and **8-b**, which
649 have an L-shaped structure and are self-prevented from aggregation in
650 aqueous mediums. The photophysical and photochemical properties - for
651 example, singlet oxygen quantum yields, low photobleaching and partition
652 coefficient (log P) made **8-a** and **8-b** better photosensitizer candidates for PDT
653 compared to verteporfin. The cytotoxicity of the chlorin derivatives in the tumour
654 cells was 60% higher than verteporfin, which allowed lower concentrations to be
655 used to have a targeted effect. Fluorescence microscopy showed that the
656 mechanism of cell death occurs by a highly apoptotic process in the three cell
657 lines after irradiation. Therefore, we suggest that the new chlorin derivatives **8-a**
658 and **8-b** exhibit strong potential as photosensitizer, and they should be
659 evaluated further in animal models and other PDT studies.

660

661 **Acknowledgements**

662

663 The authors wish to thank the CNPq, FAPESP (2015/21110-4), CEPOF
664 (2013/07276-1) and CAPES for financial support and fellowships, as well as
665 Prof. Ilce Mara de Syllos Cólus for kindly providing the HeLa cell line. We are very
666 grateful to Dr. Mauricio S. Baptista for allow us to do the measurements of
667 singlet oxygen quantum yield in his lab and to Dr. Helena Junqueira for
668 performing the experiments.

669

670

671 **References**

672

- 673 [1] Asano R, Nagami A, Fukumoto Y, Miura K, Yazama F, Ito H, et al.
674 Synthesis and biological evaluation of new boron-containing chlorin
675 derivatives as agents for both photodynamic therapy and boron neutron
676 capture therapy of cancer. *Bioorg Med Chem Lett*. 2014;24:1339–43.
- 677 [2] Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic
678 therapy: part two-cellular signaling, cell metabolism and modes of cell
679 death. *Photodiagnosis Photodyn Ther*. 2005;2(1):1–23.
- 680 [3] Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a
681 short review on cellular mechanisms and cancer research applications for
682 PDT. *J Photochem Photobiol B*. 2009;96(1):1–8.
- 683 [4] Asano R, Nagami A, Fukumoto Y, Yazama F, Ito H, Sakata I, et al.
684 Synthesis and biological evaluation of new chlorin derivatives as potential
685 photosensitizers for photodynamic therapy. *Bioorg Med Chem*.
686 2013;21:2298–304.
- 687 [5] Gorman A, Killoran J, O'Shea C, Kenna T, Gallagher WM, O'Shea DF. In
688 vitro demonstration of the heavy-atom effect for photodynamic therapy. *J*
689 *Am Chem Soc*. 2004;126:10619–31.
- 690 [6] Goncalves NPF, Simoes AVC, Abreu AJ, Abrunhosa AJ, Dabrowski JM,
691 Pereira MM. Synthesis and biological distribution study of a new carbon-
692 11 labeled porphyrin for PET imaging. Photochemical and biological
693 characterization of the non-labeled porphyrin. *J Porphyrins*
694 *Phthalocyanines*. 2015;19:946–55.

- 695 [7] Dabrowski JM, Pereira MM, Arnaut LG, Monteiro CJ, Peixoto AF, Karocki
696 A, et al. Synthesis, photophysical studies and anticancer activity of a new
697 halogenated water-soluble porphyrin. *Photochem Photobiol.* 2007;83:897–
698 903.
- 699 [8] Ethirajan M, Chen Y, Joshi P, Pandey R. The role of porphyrin chemistry
700 in tumor imaging and photodynamic therapy. *Chemic Soc Rev.*
701 2011;40(1):340–62.
- 702 [9] Park H, Na K. Conjugation of the photosensitizer Chlorin e6 to pluronic
703 F127 for enhanced cellular internalization for photodynamic therapy.
704 *Biomaterials.* 2013;34:6992–7000.
- 705 [10] Kempa M, Kozub P, Kimball J, Rojkiewicz M, Kus P, Gryczynski Z, et al.
706 Physicochemical properties of potential porphyrin photosensitizers for
707 photodynamic therapy. *Spectrochimica Acta A Mol Biomol Spectrosc.*
708 2015;146:249–54.
- 709 [11] Simoes AVC, Adamowicz A, Dabrowski JM, Calvete MJF, Abreu AR,
710 Stochel G, et al. Amphiphilic meso(sulfonate ester fluoroaryl)porphyrins:
711 refining the substituents of porphyrin derivatives for phototherapy and
712 diagnostics. *Tetrahedron.* 2012;68:8767–72.
- 713 [12] Quartarolo AD, Perusse D, Dumoulin F, Russo N, Sicilia E. Hydrophilic
714 annulated dinuclear zinc(II) phthalocyanine as Type II photosensitizers for
715 PDT: a combined experimental and (TD)-DFT investigation. *J Porphyrins*
716 *Phthalocyanines.* 2013;17:980–8.
- 717 [13] Ongarora BG, Hu X, Li H, Fronczek FR, Vicente MGH. Syntheses and
718 properties of trimethylaminophenoxy-substituted Zn(II)-phthalocyanines.
719 *Med Chem Comm.* 2012;3:179–94.

- 720 [14] Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin EV. Biomodulatory
721 approaches to photodynamic therapy for solid tumors. *Cancer Lett.*
722 2012;326(1):8–16.
- 723 [15] Dabrowski JM, Arnaut LG. Photodynamic therapy (PDT) of cancer: from
724 local to systemic treatment. *Photochem Photobiol Sci* 2015;14:1765–80.
- 725 [16] Li K, Guo C, Chen Q. Efficient One-Pot Regioselective Synthesis of 2,3-
726 Dibromo-5,10,15,20-tetraarylporphyrins from 5,10,15,20-Tetraarylchlorins.
727 *Synlett.* 2009:2867–71.
- 728 [17] de Assis FF, de Souza JM, Assis BHK, Brocksom TTJ, de Oliveira K.
729 Synthesis and photophysical studies of a chlorin sterically designed to
730 prevent self-aggregation. *Dyes Pigments.* 2013;98:153–9.
- 731 [18] Yoon I, Kim JH, Li JZ, Lee WK, Shim YK. Efficient Photosensitization by a
732 chlorin-polyoxometalate supramolecular complex. *Inorg Chem.*
733 2014;53(1):3–5.
- 734 [19] Isakau HA, Parkhats MV, Knyukshto VN, Dzhagarov BM, Petrov EP,
735 Petrov PT. Toward understanding the high PDT efficacy of chlorin e6-
736 polyvinylpyrrolidone formulations: photophysical and molecular aspects of
737 photosensitizer-polymer interaction *in vitro*. *J Photochem. Photobiol B.*
738 2008;92:165–74.
- 739 [20] Szurko A, Rams M, Sochanik A, Sieron-Stoltny K, Kozielec AM, Montforts
740 FP, et al. Spectroscopic and biological studies of a novel synthetic chlorin
741 derivative with prospects for use in PDT. *Bioorg Med Chem.*
742 2009;17:8197–205.

- 743 [21] Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII-verteporfin for
744 targeted photodynamic therapy in a rat model of choroidal
745 neovascularization. *Invest Ophthalmol Vis Sci.* 2009;50:3890–6.
- 746 [22] Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and
747 choroidal thickness after verteporfin photodynamic therapy for polypoidal
748 choroidal vasculopathy. *Am J Ophthalmol.* 2011;151:594–603.
- 749 [23] Ericson M, Grapengiesser S, Gudmundson F, Wennberg A, Larko O,
750 Moan J, et al. A spectroscopic study of the photobleaching of
751 protoporphyrin IX in solution. *Laser Med Sci.* 2003;18(1):56-62.
- 752 [24] Eshghi H, Sazgarnia A, Rahimizadeh M, Attaran N, Bakavoli M,
753 Soudmand S. Protoporphyrin IX-gold nanoparticle conjugates as an
754 efficient photosensitizer in cervical cancer therapy. *Photodiagnosis*
755 *Photodyn Ther.* 2013;10:304–12.
- 756 [25] Pavlov VY. Modern aspects of the chemistry of protoporphyrin IX. *Russian*
757 *J Org Chem.* 2007;43(1):1–34.
- 758 [26] Karim SP, Adelman RA. Profile of verteporfin and its potential for the
759 treatment of central serous chorioretinopathy. *Clin Ophthalmol.*
760 2013;7:1867–75.
- 761 [27] Mak ST, Wong AC. Single-session combined photodynamic therapy with
762 verteporfin and intravitreal anti-vascular endothelial growth factor therapy
763 for chronic central serous chorioretinopathy: a pilot study at 12-month
764 follow-up. *Graefes Arch Clin Exp Ophthalmol.* 2013;251:401–2.
- 765 [28] Nowak-Sliwinska P, Karocki A, Elas M, Pawlak A, Stochel G, Urbanska K.
766 Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers

- 767 against melanoma cells. *Biochem Biophys Res Commun.* 2006;349:549–
768 55.
- 769 [29] Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S.
770 Photodynamictherapy of cancer. Basic principles and applications. *Clin*
771 *Transl Oncol.* 2008;10:148–54.
- 772 [30] Silbergleit AK, Somers ML, Schweitzer VG, Gardner GM, Peterson E.
773 Vocal fold vibration after photofrin-mediated photodynamic therapy for
774 treatment of early-stage laryngeal malignancies. *J Voice.* 2013;27:762–4.
- 775 [31] Paszko E, Vas GM, Ehrhardt C, Senge MO. Transferrin conjugation does
776 not increase the efficiency of liposomal Foscan during in vitro
777 photodynamic therapy of oesophageal cancer. *Eur J Pharm Sci.*
778 2013;48:202–10.
- 779 [32] Leung WN, Sun X, Mak NK, Yow CM. Photodynamic effects of mTHPC on
780 human colon adenocarcinoma cells: photocytotoxicity, subcellular
781 localization and apoptosis. *Photochem Photobiol.* 2002;75:406–11.
- 782 [33] Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, et al.
783 Photodynamic therapy using Laserphyrin for centrally located early stage
784 lung cancer. *J Clin Oncol.* 2006;24(18):7229.
- 785 [34] Namatame H, Akimoto J, Matsumura H, Haraoka J, Aizawa K.
786 Photodynamic therapy of C6-implanted glioma cells in the rat brain
787 employing second-generation photosensitizer talaporfin sodium.
788 *Photodiagnosis Photodyn Ther.* 2008;5:198–209.
- 789 [35] Josefsen LB, Boyle RW. Photodynamic therapy and the development
790 metal-based photosensitisers. *Met Based Drugs.* 2008;2008:1–23.

- 791 [36] Allison PR, Sibata CH. Oncologic photodynamic therapy photosensitizers:
792 a clinical review. *Photodiagnosis Photodyn Ther.* 2010;7:61–75.
- 793 [37] Yano S, Hirohara S, Obata M, Hagiya Y, Ogura S, Ikeda A, et al. Current
794 states and future views in photodynamic therapy. *J Photochem Photobiol*
795 *C-Photochem Rev.* 2011;12(1):4–67.
- 796 [38] dos Santos FAB, Uchoa AF, Baptista MS, Iamamoto Y, Serra OA,
797 Brocksom TJ, et al. Synthesis of functionalized chlorins sterically-
798 prevented from self-aggregation. *Dyes Pigments.* 2013;99:402–11.
- 799 [39] de Oliveira KT, Silva AMS, Tome AC, Neves MGPMS, Neri CR, Garcia
800 VS, et al. Synthesis of new amphiphilic chlorin derivatives from
801 protoporphyrin-IX dimethyl ester. *Tetrahedron.* 2008;64:8709–15.
- 802 [40] Nakae Y, Fukusaki E, Kajiyama S, Kobayashi A, Nakajima S, Sakata I.
803 Syntheses and screening tests of new chlorin derivatives as
804 photosensitizer. *J Photochem Photobiol A-Chem.* 2005;174:187–93.
- 805 [41] Uchoa AF, de Oliveira KT, Baptista MS, Bortoluzzi AJ, Iamamoto Y, Serra
806 OA. Chlorin photosensitizers sterically designed to prevent self-
807 aggregation. *J Organ Chem.* 2011;76:8824–32.
- 808 [42] Armarego WLF, Chai CLL. *Purification of laboratory chemicals.* 6th ed.
809 Burlington, Massachusetts, USA: Elsevier; 2009.
- 810 [43] Engel T, Kickelbick G. Thermoreversible Reactions on Inorganic
811 Nanoparticle Surfaces: Diels-Alder Reactions on Sterically Crowded
812 Surfaces. *Chem Materials.* 2013;25(2):149–57.
- 813 [44] Heath WH, Palmieri F, Adams JR, Long BK, Chute J, Holcombe TW, et al.
814 Degradable cross-linkers and strippable imaging materials for step-and-
815 flash imprint lithography. *Macromol.* 2008;41:719–26.

- 816 [45] Wilkinson F, Helman WP, Ross AB. Rate constants for the decay and
817 reactions of the lowest electronically excited singlet-state of molecular-
818 oxygen in solution. An expanded and revised compilation. *J PhysChem*
819 *Ref Data*. 1995;24:663–1021.
- 820 [46] Redmond RW, Gamlin JN. A compilation of singlet oxygen yields from
821 biologically relevant molecules. *Photochem Photobiol*. 1999;70:391–475.
- 822 [47] Fery-Forgues S, Lavabre D. Are fluorescence quantum yields so tricky to
823 measure? A demonstration using familiar stationary product. *J Chem Ed*.
824 1999;76:1260–4.
- 825 [48] Engelmann FM, Rocha SV, Toma HE, Araki K, Baptista MS.
826 Determination of n-octanol/water partition and membrane binding of
827 cationic porphyrins. *Int J Pharm*. 2007;329(1-2):12–8.
- 828 [49] Merlin JL, Azzi S, Lignon D, Ramacci C, Zeghari N, Guillemin F. MTT
829 assays allow quick and reliable measurement of the response of human
830 tumour-cells to photodynamic therapy. *Eur J Cancer*. 1992;28A:1452–8.
- 831 [50] Berridge MV, Tan AS, McCoy KD, Wang R. The biochemical and cellular
832 basis of cell proliferation assays that use tetrazoliumsalts. *Biochemica*.
833 1996;4:14–9.
- 834 [51] Smith S, Ribble D, Goldstein N, Norris D, Shellman Y, Conn P. A Simple
835 Technique for Quantifying Apoptosis in 96-Well Plates. *Lab Methods Cell*
836 *Biol: Biochem Cell Culture*. 2012;112:361–8.
- 837 [52] Pellosi D, Tessaro AL, Moret F, Gaio E, Reddi E, Caetano W, et al.
838 Pluronic® mixed micelles as efficient nanocarriers for benzoporphyrin
839 derivatives applied to photodynamic therapy in cancer cells. *J Photochem*
840 *Photobiol A:Chem*. 2016;314:143–54.

- 841 [53] Nas A, Fandakli S, Kantekin H, Demirbas A, Durmus M. Novel
842 organosoluble metal-free and metallophthalocyanines bearing triazole
843 moieties: Microwave assisted synthesis and determination of
844 photophysical and photochemical properties. *Dyes Pigments*.
845 2012;95(1):8–17.
- 846 [54] Correa JC, Bagnato VS, Imasato H, Perussi JR. Previous illumination of a
847 water soluble chlorine photosensitizer increases its cytotoxicity. *Laser*
848 *Phys*. 2012;22:1387–94.
- 849 [55] Ferreira J, Menezes PFC, Kurachi C, Sibata C, Allison RR, Bagnato VS.
850 Photostability of different chlorine photosensitizers. *Laser Phys Lett*.
851 2008;5:156–61.
- 852 [56] Smith DA, Allerton C, Kalgutkar AS, Waterbeemd H, Walker DK,
853 Mannhold R, et al., editors. *Pharmacokinetics and metabolism in drug*
854 *design*. 3rd ed. Weinheim, Germany: WILEY-VCH; 2012.
- 855 [57] Pooler J, Valenzano D. Physicochemical determinants of the sensitizing
856 effectiveness for photooxidation of nerve membranes by fluorescein
857 derivatives. *Photochem Photobiol*. 1979;30:491–8.
- 858 [58] Shah SS, Laghari GM, Naeem K, Shah SWH. Partition coefficient of
859 amphiphilic chemicyanine dyes between the aqueous and the micellar
860 phase of sodium dodecyl sulfate by differential absorbance spectroscopy.
861 *Colloids Surfaces A: Physicochem Eng Aspects*. 1998;143(1):111–5.
- 862 [59] Kepczynski M, Pandian RP, Smith KM, Ehrenberg B. Do liposome-binding
863 constants of porphyrins correlate with their measured and predicted
864 partitioning between octanol and water? *Photochem Photobiol*.
865 2002;76(2):127–34.

- 866 [60] Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of
867 albumin, vascular surface area, and vascular volume measured in human
868 adenocarcinoma LS174T using dorsal chamber in SCID mice. *Microvasc*
869 *Res.* 1993;45:269–89.
- 870 [61] Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic
871 therapy: Part three- Photosensitizer pharmacokinetics, biodistribution,
872 tumor localization and modes of tumor destruction. *Photodiagnosis*
873 *Photodyn Ther.* 2005;2(2):91–106.
- 874 [62] Allison B, Pritchard PH, Levy JG. Evidence for low-density lipoprotein
875 receptor-mediated uptake of benzoporphyrin derivative. *Br J Cancer.*
876 1994;69:833–9.
- 877 [63] Korbelik M, Krosi G. Photofrin accumulation in malignant and host cell
878 populations of a murine fibrosarcoma. *Photochem Photobiol.*
879 1995;62(1):162–8.
- 880 [64] Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St Denis TG, et al.
881 Concepts and principles of photodynamic therapy as an alternative
882 antifungal discovery platform. *Front Microbiol.* 2012;3:1–16.
- 883 [65] Fruehauf JP, Meyskens FL Jr. Reactive oxygen species: a breath of life or
884 death? *Clin Cancer Res.* 2007;13:789–94.